Pmgroup Worldwide Ltd company information, Employees & Contact Information

Medherant announces positive phase 1 results for testosterone patch for women PMLiVE

From insight to impact: strengthening stakeholder engagement across the patient journey PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn PMLiVE

Corcept Therapeutics reports positive phase 3 results in ovarian cancer treatment PMLiVE

ProImmune expands into new global headquarters in Oxford PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy PMLiVE

PMLiVE’s T40 – now open for submissions! PMLiVE

AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer PMLiVE

AstraZeneca unveils plans to boost US footprint with $50bn investment PMLiVE

ISPEP launches International Patient Engagement Day 2025 PMLiVE

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer PMLiVE

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition PMLiVE

MHRA marks 100 years of patient safety through biological standards PMLiVE

Smarter strategies for systematic literature reviews PMLiVE

Pharmaceutical Market Europe – July/August 2025 PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults PMLiVE

Are digital communications losing the human touch? PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn PMLiVE

The evolution of AI in clinical trials: from promise to practice PMLiVE

Examining the health of the pharma: patient group relationship PMLiVE

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type PMLiVE

Indegene acquires BioPharm to advance AI-driven life sciences marketing PMLiVE

Ireland’s largest cancer research initiative launches second phase PMLiVE

PMLiVE’s Top Pharma list is live PMLiVE

Pfizer agrees pricing and distribution deal with US government PMLiVE

Pfizer and Flagship Pioneering enter autoimmune disease partnership PMLiVE

FDA unveils PreCheck programme to enhance US domestic pharma supply chain PMLiVE

GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval PMLiVE

Roche’s Evrysdi tablets granted EC approval to treat spinal muscular atrophy PMLiVE

Sanofi unveils $20bn US investment to boost R&D and manufacturing presence PMLiVE

Roche to boost US footprint with $50bn investment over next five years PMLiVE

FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata PMLiVE

Rare Disease Day 2025 – highlighting recent approvals in the rare disease space PMLiVE

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC PMLiVE

The delicate balancing act of incorporating technology into healthcare PMLiVE

Pharmaceutical Market Europe – March 2025 PMLiVE

Lilly to invest $5bn in US manufacturing facility PMLiVE

Jason Reese appointed as VML Health’s global chief transformation officer PMLiVE

Winning commercial’s AI race with connected CRM and data PMLiVE

EU medicine shortages hit record highs in 2023 and 2024 PMLiVE

Are botanical drugs part of the future of medicine? PMLiVE

The future of customer engagement in biopharma PMLiVE

Omnichannel: from theory to successful implementation PMLiVE

Boehringer Ingelheim and Salipro Biotech enter drug development partnership PMLiVE

Launch excellence: innovative thinking meets insightful strategy PMLiVE

FDA unveils new voucher programme to accelerate drug review process PMLiVE

DEBRA and Queen Mary partner to advance epidermolysis bullosa drug development PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare blood disorder PNH PMLiVE

Maximising the potential of AI in pharma PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn PMLiVE

Sanofi gains access to Alzheimer’s candidate through $470m Vigil acquisition PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis PMLiVE

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval PMLiVE

Communiqué 2025: celebrating excellence in healthcare communications PMLiVE

Building inclusive clinical trials through policy reform PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition PMLiVE

Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication PMLiVE

Novartis to invest $23bn into US-based infrastructure over next five years PMLiVE

Beyond the badge: communicating the business case for DEI PMLiVE

Better together – accelerating innovation and access to rare disease treatments PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer PMLiVE

New survey: Europeans seek better health equity in breast cancer awareness PMLiVE

From spark to surge: rethinking partnerships in healthcare communications PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever PMLiVE

Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations PMLiVE

Empathy is not a soft skill – it’s a strategic one PMLiVE

FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours PMLiVE

Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM PMLiVE

FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU PMLiVE

Avalere Health appoints Jocelyn Crouch as head of brand strategy PMLiVE

New centre for life sciences launched in London PMLiVE

J&J’s Darzalex Faspro recommended by FDA panel of experts for smouldering multiple myeloma PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition PMLiVE

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer PMLiVE

Bridging the gap: from awareness to action in health equity PMLiVE

Health misinformation: can pharma really have an impact? PMLiVE

Fox&Cat appoints Kim Walker as partner and managing director PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease PMLiVE

Biogen initiates phase 3 study of felzartamab in kidney transplant patients PMLiVE

Breaking boundaries in medical affairs: how measurable outcomes redefine success PMLiVE

Conferences: the value of real experience versus virtual convenience PMLiVE

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing PMLiVE

Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m PMLiVE

AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC PMLiVE

Why Pharma’s Digital PI Compliance Problem Needs a Cross-Functional Fix PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn PMLiVE

How AI can humanise data and transform healthcare communications PMLiVE

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia PMLiVE

The power of purpose PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition PMLiVE

J&J receives three CHMP recommendations for immunology and oncology indications PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn PMLiVE

AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer PMLiVE